LAM Therapeutics, a portfolio company of Connecticut biotech start-up incubator 4Catalyzer, closed a $40 million financing to advance lead programs, LAM-001, an inhaled mTOR kinase Inhibitor in phase I development to treat lymphangioleiomyomatosis – also known as LAM lung disease – and LAM-002, a selective kinase inhibitor that is cytotoxic for certain cancers with little or no effect on normal cells.